Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
- Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
- Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
Nov 15, 2022 at 12:35 PM EST
Nov 4 - Nov 8, 2022
Oct 18, 2022 from 12:00 PM to 12:30 PM EDT